SCHEMBL16836629

SCHEMBL16836629

CC(C)(O)c1csc(N2CCCNCC2)n1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.47
BAZ2A Q9UIF9 7/20 0.41
AOC3 Q16853 1/20 0.39
PRKCI P41743 3/20 0.38
HRH4 Q9H3N8 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
CHRNB2 P17787 1/20 0.37
CHRNA4 P43681 1/20 0.37
HRH1 P35367 1/20 0.37
USP2 O75604 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CASP1 P29466 1/20 0.36
CASP4 P49662 1/20 0.36
CASP5 P51878 1/20 0.36
NCF1 P14598 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3160202 0.82 LMNA (0.67) LMNABAZ2AAOC3HRH4HRH3
SCHEMBL9794803 0.81 BAZ2A (0.48) BAZ2APRKCIHRH4HRH3HRH1
Hydrochloric Acid SCHEMBL17541653 0.81 LMNA (0.65) LMNABAZ2AAOC3
SCHEMBL2826722 0.76 ADRB1 (0.49) LMNABAZ2AAOC3HRH1
SCHEMBL5229175 0.75 BAZ2A (0.48) LMNABAZ2AAOC3
Hydrochloric Acid SCHEMBL2273378 0.75 ADRB1 (0.48) LMNABAZ2AAOC3HRH1
SCHEMBL2228747 0.74 BAZ2A (0.49) LMNABAZ2AAOC3HRH3SMN1; SMN2
SCHEMBL10236327 0.74 LMNA (0.73) LMNASMN1; SMN2
Hydrochloric Acid SCHEMBL17541490 0.72 BAZ2A (0.48) LMNABAZ2AAOC3HRH3SMN1; SMN2
SCHEMBL19846720 0.72 LMNA (0.71) LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9732077-B2 Diazepane orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2017-08-15 US disclosed
US-9732077-B2 Diazepane orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2017-08-15 US disclosed
US-9732077-B2 Diazepane orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2017-08-15 US disclosed
US-20160318923-A1 DIAZEPANE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2016-11-03 US disclosed
US-20160318923-A1 DIAZEPANE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2016-11-03 US disclosed
US-20160318923-A1 DIAZEPANE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2016-11-03 US disclosed
WO-2015095111-A1 DIAZEPANE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2015-06-25 WO disclosed
WO-2015095111-A1 DIAZEPANE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2015-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160318923-A1 DIAZEPANE OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, CRHR1 LMNA 3650/4885BAZ2A 486/4885AOC3 392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.